Monopar Therapeutics
Close on Oct 19, 2026
- Market cap
- $610.53M
- P/E (TTM)
- –
- Dividend yield
- –
About Monopar Therapeutics
Pharmaceutical Preparations, SIC 2834
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for Wilson disease and targeted radiopharmaceuticals for oncology. Its primary therapeutic asset is ALXN1840, an investigational oral small molecule designed to bind and remove copper in Wilson disease patients. The company's oncology pipeline consists of uPAR-targeted radiopharmaceutical candidates, including MNPR-101-Zr for diagnostic imaging, MNPR-101-Lu for radioimmunotherapy, and preclinical MNPR-101-Ac for treating advanced solid cancers. Monopar develops its pipeline through internal programs and strategic licensing, aiming to serve individuals affected by rare genetic disorders and advanced malignancies.
The company conducts clinical activities across multiple international jurisdictions, including Phase 1 clinical trials and human imaging studies in Australia, as well as an expanded access program operating in Houston, Texas. Intellectual property rights for its development pipeline encompass patent portfolios in over 30 countries, including the United States and Japan. Third-party contract manufacturing organizations handle all raw materials and clinical batch production. The company is based in the United States.
Summary of the business section of Monopar Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Monopar Therapeutics
- Founded
- 2014
- Headquarters
- Wilmette, IL
- Address
- 1000 Skokie Blvd Suite 350 60091
- Phone
- (847) 388-0349
- Website
- www.monopartx.com
- Employees
- 22, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- BPM LLP, Santa Rosa, California
Stock & identifiers
- Ticker
- MNPR
- Exchange
- Nasdaq
- IPO date
- Dec 19, 2019
- Shares outstanding
- 7M, Jul 31, 2026
- Public float
- $155.53M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-5 reverse, Nov 8, 2024; 1-for-5 reverse, Aug 13, 2024
- SEC CIK
- 1645469
- CUSIP
- 61023L207
- ISIN
- US61023L2079
- LEI
- 549300QJFAI7L6YHKG83
- EIN
- 32-0463781
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Chandler Robinson | Chief Executive Officer, Director | 191,138 |
| Pharma LLC Tactic | Chief Executive Officer, Director | 4,383,299 |
| Quan Anh Vu | Chief Financial Officer | 2,221 |
| Andrew Cittadine | Chief Operating Officer | 57,923 |
| Susan Rodriguez | CCSO | – |
| Karthik Radhakrishnan | Chief Financial Officer | 1,550 |
| Raymond Anderson | Director | 5,373 |
| Kim R. Tsuchimoto | Director | 12,678 |
| Nicole Sweeny | Director | – |
| Arthur J. Klausner | Director | 3,064,156 |
| Lavina Talukdar | Director | 14,001 |
| Christopher M. Starr | Director | 31,853 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Chandler D. Robinson | $10.64M | $17.38M | $2.32M | $3839 | – |
| FY2024 Chandler D. Robinson | $1.14M | $2.36M | $437.48K | $186 | – |
| FY2023 Chandler D. Robinson | $1.78M | -$166.18K | $879.81K | $14 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of March 17, 2026, we had twenty-two employees, all were full-time.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 24, 2024 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Feb 28, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Aug 30, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Dec 19, 2019 | IPO | Initial public offering priced (424B4 prospectus) |
| Sep 30, 2019 | Listing | Registration of securities on an exchange (Form 8-A) |